Hansen's Disease (Leprosy)

Current and Future Pharmacotherapy and Treatment of Disease-related Immunologic Reactions

Davey P. Legendre, Pharm.D.; Christina A. Muzny, M.D.; Edwin Swiatlo, M.D., Ph.D.


Pharmacotherapy. 2012;32(1):27-37. 

In This Article


Hansen's disease (leprosy) remains problematic in the United States and throughout the world. Transmission of bacteria from person to person is uncommon, and armadillos remain the major reservoir in the United States. There is no efficient way to grow the organism in culture, which makes research efforts difficult. Prompt recognition of disease and treatment reduces disease signs and symptoms, such as anesthetic lesions, loss of vision, and amputation. The discovery of antibacterial therapy targeting M. leprae has dramatically improved those infected with Hansen's bacillus. Patients benefit from comprehensive care involving numerous health care professionals. Astute pharmacists who effectively manage antibacterial and reaction therapy will notice improved patient outcomes and quality of life. Major complications today involve immunologic reactions and drug resistance due to lack of compliance. Clinicians can recognize these issues early and adjust treatment appropriately to limit long-term complications from this disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.